Fierce Pharma May 24, 2024
In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV).
The agency doled out the PRV after determining that Pfizer’s COVID-19 antiviral Paxlovid meets the bar for classification as a medical countermeasure to a material threat, according to a notice (PDF) in the Federal Register. Paxlovid won its full FDA approval about one year ago.
Such vouchers, an extra incentive for developing treatments against diseases with high unmet need, have proven to be quite lucrative. Companies can either use them to speed up high-stakes drug reviews at the FDA or sell them to other drug developers.
A...
Today's Sponsors
Today's Sponsor